NEW YORK, Nov. 28 – Invitrogen has acquired the exclusive rights to develop and market genotyping products utilizing Orchid’s SNP-scoring primer extension technology in a 96-well format, the companies said Wednesday.
Under the terms of the deal, Invitrogen of San Diego will pay Orchid of Princeton, NJ, a royalty on kit sales.
"The agreement with Orchid is consistent with our strategy of in-licensing high potential technologies,” Lyle Turner, CEO of Invitrogen, said in a statement. “Now we can bring the premier technology for accurate, rapid and flexible SNP genotyping to scientists worldwide."
Invitrogen has also obtained the rights to provide customers with access to the SNP primer design algorithms Orchid provides through its AutoPrimer.com website.
Orchid said that it would benefit from Invitrogen’s marketing and sales infrastructure.
"With their worldwide sales and marketing coverage, Invitrogen is an acknowledged leader in providing technically advanced reagent kits to thousands of laboratories," Jack Ball, senior vice president and general manager of Orchid's Life Sciences Group, said.
Orchid's proprietary SNP-IT primer extension technology provides is designed to allow researchers to generate hundreds of SNP genotypes per day.